Dyadic International, Inc. (OTCQX: DYAI) is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, according to the company’s website (see here: www.Dyadic.com). SNNLive caught up with Mark Emalfarb, CEO of Dyadic International, Inc. at the Dawson James Small Cap Growth Conference 2015 in Jupiter, FL.
In this video interview, Mr. Emalfarb and our host discuss the following topics:
- Overview of Dyadic International, Inc.
- Describes the company’s technology for producing proteins and enzymes
- How the company works with their customer base
- Recent corporate developments
- Target markets for company’s proteins and enzymes
For more information about Dyadic International, Inc., go to: www.Dyadic.com
The interview may contain forward looking statements about Dyadic International, Inc. See Dyadic’s periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions